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Abstract
Introduction: This study was aimed at understanding the clinicopathological significance of cystatin M loss, and
investigating possible factors responsible for cystatin M loss in breast cancer.
Methods: The expression of estrogen receptor (ER), progesterone receptor (PR), HER2, HER4, and cystatin M was
retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (DCIS) and in
175 patients with invasive breast cancer (IBC). The methylation status of CST6 gene encoding cystatin M was
evaluated using methylation-specific polymerase chain reaction (PCR) in formalin-fixed paraffin-embedded tissues
from 292 participants and using pyrosequencing in fresh-frozen tumor and matched normal tissues from 51 IBC
patients.
Results: Cystatin M loss was found in 9 (8%) of 117 patients with DCIS and in 99 (57%) of 175 with invasive breast
cancer (IBC) (P < 0.0001). Cystatin M loss was found in 58 (57%) of 101 HER2-negative IBCs and in 41 (55%) of 74
HER2-positive IBCs, and this difference was not statistically significant (P = 0.97). However, cystatin M loss was
significantly associated with the loss of ER (P = 0.01), PR (P = 0.002), and HER4 (P = 0.003) in IBCs. Cystatin M loss
occurred in 34 (76%) of the 45 HER4-negative IBCs and in 65 (50%) of the 130 HER4-positive IBCs. Multivariate analysis
showed that cystatin M loss occurred at a 3.57 times (95% CI = 1.28 to 9.98; P = 0.01) higher prevalence in the triple-
negative IBCs of ER, PR, and HER4 than in other subtypes, after adjusting for age. The quantity of CST6 methylation
was associated with ER loss (P = 0.0002) in IBCs but not with the loss of PR (P = 0.64) or HER4 (P = 0.87).
Conclusions: The present study suggests that cystatin M loss may be associated with the losses of ER, PR, and
HER4 in IBC.
Introduction
Ductal carcinoma in situ (DCIS) of the breast is the most
common type of noninvasive breast cancer in women
and accounts for 20 to 30% of breast cancer detected by
screening mammography [1,2]. Abnormal cells in DCIS
are confined to the lactiferous ducts in the breast and do
not spread into the surrounding stroma. However,
further changes in cells comprising DCIS lesions result
in the destruction of the basement membrane that
surrounds the duct and in the spread of tumor cells into
the surrounding tissue. Lysosomal cysteine proteases are
involved in the degradation of components of the extra-
cellular matrix in vitro, and increased activity of these
proteases leads to the destruction of the extracellular gly-
coprotein scaffolds that maintain tissue architecture, thus
facilitating invasion of cancer cells beyond the basement
membrane.
Cystatin M is a candidate tumor suppressor that func-
t i o n sa sap h y s i o l o g i c a li n h i b itor of lysosomal cysteine
proteases. Cystatin M is abundantly expressed in normal
and premalignant breast epithelium, but its expression
has been reported to be diminished or lost in breast
cancers [3-7]. The loss of cystatin M expression is
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metastatic phenotype [3,4,7]. Furthermore, exogenous
expression of recombinant cystatin M results in the sup-
pression of cell proliferation, migration, and matrix inva-
sion in vitro [8]. The CST6 gene encoding cystatin M
contains a large CpG island that spans the proximal
promoter and exon 1, encompassing the transcription
start site. Several groups have reported DNA methyla-
tion-dependent silencing of CST6 gene in breast cancer
cell lines and primary invasive ductal carcinomas, but
the upstream initiators that direct this process have not
been elucidated [5,6].
Recently, Leu et al. [9] reported that disruption of the
estrogen receptor ERa in breast cancer cells resulted in
DNA methylation of ERa target genes. In addition, a
number of studies have reported a unique relationship
between ER and HER4 in breast cancer [10-14]. Zhu
et al. [14] reported that ER and HER4 can target estro-
gen-inducible gene promoters such as stromal cell-
derived factor 1 (SDF-1), a putative key player of the
matrix remodeling. Based on these reports, we hypothe-
sized that cystatin M may be a downstream target of ER
and/or HER4 and that CST6 methylation may be influ-
enced by the alteration of ER and/or HER4. To investi-
gate the clinicopathological significance of cystatin M
loss and to identify possible factors associated with
cystatin M loss in breast cancer, we analyzed the expres-
sion status of five proteins (ER, PR, HER2, HER4, and
cystatin M) and the hypermethylation of CST6 gene in a
total of 292 breast cancer patients.
Materials and methods
Study population
A total of 117 DCIS and 175 IBC patients participated in
this study. Pure DCIS cases were included in this study,
and DCIS lesions associated with invasive breast cancer
were excluded. All specimens were obtained from
patients who underwent surgical resection for DCIS and
IBC between May 2001 and July 2006 at the Samsung
Medical Center in Seoul, Korea. Written informed con-
sent for the use of the surgically resected tumor tissues
was provided by all of the DCIS and IBC patients prior to
operation. Paired samples of primary breast cancer and
matched noncancerous normal tissues were obtained
from each patient. Surgically removed tissues were
immediately snap-frozen in liquid nitrogen and stored at
-80°C until use. All procedures used in this study were
approved by the Institutional Review Board at the Sam-
sung Medical Center. Information regarding demo-
graphics and lifestyle factors was obtained from an
interviewer-administered questionnaire. Patient age
ranged from 28 to 72 years for DCISs and from 25 to
83 years for IBCs. The pathologic stage of the IBC was
classified according to the American Joint Committee on
Cancer (AJCC) TNM criteria (sixth edition).
Tissue microarrays and immunohistochemistry
Tissue microarrays (TMAs) of DCISs and IBCs were pre-
pared as described previously [15]. Briefly, tissue sections
of four-micrometer-thickness were taken from the TMA
blocks for immunohistochemistry and deparaffinized in
xylene and rehydrated through a series of alcohols. The
rehydrated sections were treated with 3% hydrogen per-
oxide in methanol for 10 minutes to block endogenous
peroxidase. To unmask the antigens, sections were
microwaved in citrate buffer (pH 6) for a total of 15 min-
utes. Sections were incubated with a primary antibody
overnight at room temperature after blocking nonspecific
proteins with 2% dried milk in phosphate-buffered saline
(PBS) for 30 minutes and 5% goat serum in PBS for 1 h.
The antibodies used were ER (clone 6F11, Novocastra,
Vision Systems Inc., Norwe l l ,M A ,U S A ,d i l u t e da t
1:400), PR (clone 16, Novoc a s t r a ,d i l u t e da t1 : 8 0 0 ) ,
C-erb2 (clone CB11, Novocastra, diluted at 1:400),
C-erb4 (clone HFR-1, Neomarkers, Fremont, CA, USA,
diluted at 1:30), and cystatin M (clone 211515, R&D Sys-
tems, Minneapolis, MN, USA, diluted at 1:20). Detection
of immunoreactivity by each antibody was performed by
the Vectastain Elite ABC reagent (Vector Laboratories,
Burlingame, CA, USA) and 3.3’-diaminobenzidine tetra-
hydrochloride was used as a chromogen. All sections
were counterstained with Mayer’s hematoxylin, and
negative controls were included in each staining
sequence and obtained by omitting the primary antibo-
dies. Cytokeratin 8/18 (Invitrogen, Carlsbad, CA, USA;
Cat. No. 18-0213) was used as a positive control of stain-
ing to verify that tissues were stained. Representative
stainings of ER, PR, HER2, HER4 and cystatin M expres-
sion in DCISs and IBCs are shown in Figure 1.
Interpretation of immunohistochemistry
Cutoff values for positive or negative expression were
determined considering widely accepted criteria among
previously reported studies and expression patterns in
our normal tissues (data not shown). The positivity of
expression was assessed semiquantitatively by evaluating
the percentage of positive staining cells and/or staining
intensity. The expression of ER and PR was determined
according to the Allred score. If the sum of both scores
is more than three, the expression of ER and PR was
considered positive. HER2 expression was considered as
positive when moderate to strong membrane immunor-
eactivity was observed in more than 10% of tumor cells.
The membrane or nuclear staining of HER4 was not
considered in the final data analysis due to low fre-
quency (< 5%) of the staining in IBCs. Only cytoplasmic
Ko et al. Breast Cancer Research 2010, 12:R100
http://breast-cancer-research.com/content/12/6/R100
Page 2 of 9reactivity was considered evidence of HER4 as well as
cystatin M expression. An immunoreactive score (IS) of
0 to 7 for HER4 or cystatin M expression was obtained
by adding the intensity score (0, none; 1, weak; 2, mod-
erate; 3, strong) and a proportion score of positive stain-
i n gt u m o rc e l l s( 0 ,a b s e n t ;1 ,0t o1 0 % ;2 ,1 0t o5 0 % ;3 ,
50 to 80%; 4, >80%). If the IS was less than two, the
tumor was considered to exhibit loss of HER4 or cysta-
tin M expression.
Methylation-specific PCR (MSP)
Genomic DNA was extracted from fresh-frozen tissues
and formalin-fixed paraffin-embedded tissues using a
DNeasy Tissue Kit (Qiagen, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. The methylation
status of the CST6 gene in the formalin-fixed paraffin-
embedded tissues was determined using methylation-
specific PCR (MSP), as described by Herman et al.[ 1 6 ] .
The MSP primers specific for the methylated CST6 gene
were 5’-GTTTTTTGAATTTCGTAGGATTTC-3’
(sense) and 5’- AACTTTTACCCGCTAAACCG-3’ (anti-
sense). The primers for the unmethylated CST6 gene
were 5’-GGTTTTTTGAATTTTGTAGGATTTT-3’
(sense) and 5’- CAACTTTTACCCACTAAACCACC -3’
(antisense). The PCR conditions for DNA amplification
consisted of 1 cycle at 95°C for 7 minutes; 35 cycles at
94°C for 30 s, 65°C (for M primer set) or 63°C (for U pri-
mer set) for 1 minute, 72°C for 1 minute; and final exten-
sion at 72°C for 10 minutes. DNA from the peripheral
blood lymphocytes of healthy subjects was used as a
negative control for the methylation-specific assays. Lym-
phocyte DNA from healthy volunteers was treated with
Sss1 methyltransferase (New England BioLabs, Beverly,
MA, USA), and then with sodium bisulfite. The resulting
product was used as a positive control for methylated
alleles. Bisulfite-modified DNA from normal lymphocytes
was used as a positive control for unmethylated alleles,
and the unconverted DNA from normal lymphocytes was
used as a negative control for the methylated alleles.
Pyrosequencing for quantitative analysis of CST6
methylation
Fresh-frozen tissues for pyrosequencing were available
in only 51 IBC patients. The methylation status of CST6
gene in the fresh-frozen tissues was analyzed by pyrose-
quencing using a forward primer and a biotinylated
Figure 1 Representative immunohistochemical statinings of ER, PR, HER2, HER4, and cystatin M in DCIS and IBC lesions. The positive
(upper row) and negative (lower row) immunostainings for cystatin M, ER, PR, HER2, and HER4 are shown in DCISs and IBCs. Most cells in the
upper row of DCIS and IBC lesions show strong nuclear reactivity for ER and PR, strong membrane reactivity for HER2, and strong cytoplasmic
staining for HER4 and cystatin M. Magnification × 400.
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AB, Uppsala, Sweden). The primer sequences for pyro-
sequencing were as follows: 5’-GGTTTTTTGGGTT
TTTTGAA-3’ (forward), 5’-Biotin TGAGGGTTTT-
GATGGTAT-3’ (reverse) and 5’-TTGAATTTTGTAG-
GATTT-3’ (sequencing primer). Briefly, 20 ng of
sodium bisulfite-modified DNA was amplified in a 25 μl
reaction with the primer sets and 5 U of Taq polymer-
ase (Solgent Co, Daejeon, Korea). Samples were heated
at 95°C for 10 minutes and then amplified for 40 cycles
consisting of 95°C for 45 s, 55°C for 35 s and 72°C for
60 s. All reactions were then incubated at 72°C for
10 minutes and cooled to 4°C. The PCR products were
visualized on a 1.5% agarose gel by ethidium bromide
staining for verification. Pyrosequencing reactions were
hot started at 94°C for 5 minutes, and amplification was
c a r r i e do u to v e r4 5c y c l e s( 3 0sa t9 4 ° C ,3 0sa t5 8 ° C ,
3 0sa t7 2 ° C ) ,f o l l o w e db y5m i n u t e sa t7 2 ° Cw i t h
sequencing primers on the PSQ HS 96A System (Bio-
tage AB, Uppsala, Sweden) according to the manufac-
turer’s specifications. The methylation index for each
CpG in the target region was calculated using the pro-
vided software.
Statistical analysis
The normality of continuous variables was tested using
the Shapiro-Wilk test. The Wilcoxon rank-sum test (or
t-test) and Fisher’s exact test (or the Chi-squared test)
were used for the univariate analysis of the continuous
and categorical variables, respectively. A multivariate
logistic regression analysis was conducted to determine
the relationship between cystatin M loss and any covari-
ates found to be statistically significant in the univariate
analysis, and to calculate odds ratios (ORs). Covariates
with a P-value of <0.25 in the univariate analysis or any
variables that were considered to be biologically impor-
tant were subjected to the multivariate analysis. All sta-
tistical analyses were two-sided with a type I error rate
of 5%.
Results
Clinicopathological characteristics of cystatin M loss
Heterogenous staining, defined in our study as when the
staining pattern was different among cells within the
same block, is often known to be seen in epigenetically
silenced genes within advanced tumors. Heterogeneous
staining was found in 4 (3%) of 117 DCISs and in 6
(3%) of 175 IBCs. When a slide showed heterogeneous
staining, we grouped cells according to staining intensity
and calculated the immunoreactive score (IS) of 0 to 7
for cystatin M expression in each group separately. We
then calculated the mean IS in all groups. If the mean
score was less than two, the tumor was considered to
exhibit loss of cystatin M expression. The association
between cystatin M loss and clinicopathological para-
meters in 117 DCISs and 175 IBCs is shown in Table 1.
Cystatin M loss was found in 9 (8%) of the 117 DCISs
and in 99 (56%) of 175 IBCs studied (P < 0.0001). The
age of patients with DCIS or IBC was not significantly
different according to cystatin M expression (P =0 . 1 3
and P = 0.89, respectively). Cystatin M loss was found
not to be associated with tumor size in patients with
DCIS (P = 0.87) or IBC (P = 0.27). The mean tumor
size was 2.9 cm and 2.6 cm for IBC patients with and
without cystatin M loss, respectively. No association was
found between cystatin M loss and the number of
lymph nodes, family history of breast cancer in DCISs
and IBCs. Furthermore, the histologic grade was not
associated with cystatin M loss in DCISs (P =0 . 9 0 )o r
IBCs (P = 0.32). A statistically significant association
was not found between cystatin M loss and pathologic
stage in IBCs (P = 0.86).
Relationship between cystatin M loss and the expression
of ER, PR, HER2, and HER4
The prevalence of ER, PR, HER2, or HER4 loss was sig-
nificantly different between DCISs and IBCs (Table 1).
ER loss occurred in 33 (28%) of 117 DCISs and in 74
(42%) of 175 IBCs, and this difference was statistically
significant (P = 0.01). The losses of PR and HER2 also
occurred at a significantly different prevalence between
DCISs and IBCs (P =0 . 0 2a n dP = 0.008, respectively).
In addition, the prevalence of HER4 loss was 38% (44 of
117) and 26% (45 of 175) in DCISs and IBCs, respec-
tively, and this difference was also statistically significant
(P = 0.03). The relationship between cystatin M loss and
the loss of ER, PR, HER2, or HER4 was analyzed in
DCISs and IBCs (Table 1). Cystatin M loss was found in
1( 3 % )o f3 3E R - n e g a t i v eD C I S sa n di n8( 1 0 % )o f8 4
ER-positive DCISs, and this difference was not statisti-
cally significant (P = 0.44). However, the expression sta-
tus of ER in IBCs was significantly associated with
cystatin M loss (P = 0.01). Cystatin M loss occurred in
50 (68%) of 74 ER-negative IBCs and in 49 (49%) of 101
ER-positive IBCs. The relationships between cystatin M
loss and PR loss in DCISs and IBCs were similar to
those between cystatin M loss and ER loss, but HER2
loss was not significantly associated with cystatin M loss
in DCISs and IBCs (P = 0.73 and P = 0.79, respectively).
Cystatin M loss was found in 34 (76%) of the 45 HER4-
negative IBCs and in 65 (50%) of the 130 HER4-positive
IBCs and this difference was statistically significant
(P = 0.003).
Triple-negative breast cancers (TNBCs) of ER, PR, and
HER2, are known to be typically associated with poor
prognosis due to aggressive behavior of the tumor and
lack of targeted therapies. Therefore, we analyzed the
association of triple-negative status of ER, PR, and
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ER, PR, and HER2 occurred in 2 (2%) of 117 DCISs and
in 35 (20%) of 175 IBCs. However, the triple-negative
status was not associated with cystatin M loss in DCISs
(P = 1.00) and IBCs (P = 0.08), and therefore the triple-
negative status of ER, PR, and HER2 was not considered
in the further analysis. Another triple-negative status of
E R ,P R ,a n dH E R 4o c c u r r e di n1 1( 9 % )o f1 1 7D C I S s
and in 23 (13%) of 175 IBCs. For the DCIS cases, cysta-
tin M loss was not associated with the triple-negative
status of ER, PR, and HER4 (P = 1.00). However, cysta-
tin M loss in IBCs was significantly associated with the
triple-negative status of ER, PR, and HER4 (P =0 . 0 0 1 ;
Figure 2A): cystatin M loss occurred in 20 (87%) of 23
triple-negative IBCs of ER, PR, and HER4 and in 79
(52%) of 152 other subtypes. To rule out the possibility
of a confounding effect of HER2 in the relationship
between cystatin M loss and the triple-negative status of
ER, PR, and HER4, we stratified the data according to
the expression status of HER2 and reanalyzed the rela-
tionship according to HER2. However, no confounding
effect of HER2 was found in this study: cystatin M loss
occurred at a higher prevalence in the triple-negative
IBCs than in other subtypes irrespective of HER2
expression (Figure 2B).
Logistic regression analysis of cystatin M loss
In univariate logistic regression analysis (Table 2A),
cystatin M loss occurred at 2.20 times (95% confidence
interval (CI) = 1.19 to 4.06; P = 0.02) higher prevalence
in the ER-negative IBCs than in the ER-positive IBCs.
Cystatin M loss also occurred at a high prevalence in the
PR-negative IBCs (OR = 2.41, 95% CI = 1.32 to 4.39; P =
0.007) as well as in the HER4-negative IBCs (OR = 3.09,
95% CI = 1.44 to 6.62; P = 0.003) than in the PR- or
HER4-positive cases, respectively. A multivariate logistic
Table 1 Clinicopathological characteristics
DCIS IBC
Cystatin M loss Cystatin M loss
Yes (n =9 ) N o( n = 108) P-value Yes (n = 99) No (n = 76) P -value
Age
1 50 ± 9 46 ± 9 0.13 49 ± 11 49 ± 10 0.89
Tumor size (cm)
1 2.7 ± 1.8 3.0 ± 2.1 0.87 2.9 ± 1.3 2.6 ± 1.1 0.27
Number of LN
1 0 0.4 ± 1.1 0.69 2.6 ± 5.0 3.1 ± 5.9 0.83
Family history
No 9 104 92 72
Yes 0 4 1.00 7 4 0.76
Histologic grade
I1 2 4 8 8
II 5 48 42 39
III 3 36 0.90 49 29 0.32
ER
Negative 1 32 50 24
Positive 8 76 0.44 49 52 0.01
PR
Negative 3 42 62 30
Positive 6 66 1.00 37 46 0.002
HER2
Negative 3 46 58 43
Positive 6 62 0.73 41 33 0.79
HER4
Negative 7 37 34 11
Positive 2 71 0.03 65 65 0.003
Stage
I 21 14
II 55 43
III 22 18
IV 1 2 0.86
1 Mean ± standard deviation.
DCIS, ductal carcinoma in situ; IBC, invasive breast cancer; ER, estrogen receptor; PR, progesterone receptor; LN, number of involved lymph node; Family history, a
history of breast cancer within family.
Ko et al. Breast Cancer Research 2010, 12:R100
http://breast-cancer-research.com/content/12/6/R100
Page 5 of 9regression analysis was performed to control for the
potential confounding effects of variables, such as age,
and to calculate odds ratio (Table 2B). The coefficient for
age variable in IBCs was not statistically significant in our
univariate analysis (P = 0.89), but age was considered to
be biologically important and, therefore, it was included
in the multivariate analysis in order to better construct a
parsimonious model. The losses of ER, PR, and HER4
were associated with each other (data not shown), and
therefore the triple-negative status of ER, PR, and HER4
included in the multivariate logistic regression as a single
covariate. Cystatin M loss occurred at a 3.57 times (95%
CI = 1.28 to 9.98; P = 0.01) higher prevalence in the tri-
ple-negative IBCs than in other subtypes, after adjusting
age. These observations suggest that the losses of ER, PR,
and HER4 may be significantly associated with cystatin
M loss in IBCs.
The association between CST6 methylation and the loss
of cystatin M, ER, PR, or HER
Epigenetic silencing of CST6 gene in breast cancer has
been reported by several groups. To investigate whether
the loss of ER, PR, or HER4 is associated with the
hypermethylation of CpG island at the promoter region
of the CST6 gene, we analyzed the methylation status of
the CST6 gene using MSP. The primers designed for
MSP yielded an amplicon spanning from nucleotides
-108 to -2 (Figure 3A). Primers for MSP were validated
using 100% methylated and 100% unmethylated DNA
(Figure 3B). The hypermethylation of the CST6 gene by
MSP was found in 22 (20%) of 108 DCISs studied and
in 59 (34%) of 173 IBCs (Figure 3C). No association was
also found between CST6 methylation and cystatin M
loss in DCISs (P = 0.38) or IBCs (P = 0.50) (Figure 3D).
The lack of association between cystatin M loss and
hypermethylation of the CST6 g e n em a yb ed u et ot h e
density dependence of methylated CpGs on transcrip-
tional silencing by CST6 methylation or the inconsis-
tence of methylation status between primer binding sites
and other CpG sites within PCR product.
The methylation status of 13 CpG sites (Figure 3A)
in the region spanning from nucleotides -108 to -2
were, therefore, reassessed quantitatively using pyro-
sequencing in 51 fresh-frozen tissues and matched
normal tissues from IBC patients. The quantities of
methylated CpGs between normal and tumor tissues
were usually different (Figure 4A). The association
between the quantity of CST6 methylation and the
expression statuses of cystatin M, ER, PR, and HER4 in
tumor tissues was analyzed (Figure 4B). The methyla-
tion level at each CpG in tumor tissues was adjusted
by subtracting the quantity of methylated CpGs in
matched normal tissue from that of methylated CpGs
in tumor tissue. Average quantities of methylated
CpGs in tumor tissues were significantly associated
with cystatin M loss (P = 0.008; Wilcoxon rank sum
test) or ER loss (P = 0.0002; Wilcoxon rank-sum test).
The average quantities of methylated CpGs between
groups with and without ER loss were 16.4% and 8.7%,
respectively. However, the quantities of methylated
CpGs were not associated with the expression status of
PR (P = 0.64) or HER4 (P = 0.87).
Figure 2 Relationship between cystatin M loss and the triple-
negative status of ER, PR, and HER4. (A) Cystatin M loss occurred
at a higher prevalence in the triple-negative IBCs than in other
subtypes (P = 0.001). (B) The association between cystatin M loss
and triple-negative IBCs was analyzed according to the expression
status of HER2. For HER2-negative IBCs, cystatin M loss occurred in
12 (86%) of 14 triple-negative cases and in 46 (53%) of 87 other
subtypes (P = 0.02). For HER2-positive IBCs, cystatin M loss was
found in 8 (89%) of 9 triple-negative cases and in 33 (51%) of 65
other subtypes (P = 0.04). Triple-negative indicates IBCs with the
losses of ER, PR, and HER4.
Table 2 Logistic regression analysis of the association
between cystatin M loss and the losses of ER, PR, and
HER4 in IBCs (N = 175)
OR 95% CI P -value
Univariate
1
ER-negative 2.20 1.19 to 4.06 0.02
PR-negative 2.41 1.32 to 4.39 0.007
HER4-negative 3.09 1.44 to 6.62 0.003
Multivariate
2
Triple-negative 3.57 1.28 to 9.98 0.01
1 Reference was a group with expression of each protein.
2 Age was
controlled in multivariate analysis, and other subtypes with expression of
either ER, PR, or HER4 was used as a reference. Triple-negative, the losses of
ER, PR, and HER4; ER, estrogen receptor; PR, progesterone receptor; OR, odds
ratio; CI, confidence interval.
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Cystatin M is known to inhibit the activity of cystein pro-
teases which degrade extracellular matrix components. In
this study, cystatin M loss occurred in 9 (8%) of 117
patients with DCIS and in 99 (57%) of 175 patients with
IBC, supporting previous reports [3,4,7] that cystatin M
is one of many factors that are involved in the acquisition
of an invasive cellular phenotype in breast cancer. In
addition, cystatin M loss occurred more frequently in
IBCs with the losses of ER, PR, and HER4 than without,
suggesting that cystatin M expression may be influenced
by synergistic effect of those proteins. However, the
mechanism by which cystatin M expression is regulated
by ER, PR, and HER4 awaits further elucidation. The
expression statuses of ER, PR, and HER4 in this study
were significantly associated with each other (data not
shown) and PR isoforms are known to be expressed in
response to ER or independently of ER [17]. In addition,
molecules involved in cell adhesion to extracellular matix
and cytoskeletal interaction are known to be regulated by
induced PR even in the absence of ligand [18,19]. Based
on these observations, one possibility is that cystatin M
may be a downstream target of HER4-ER in IBC and be
influenced by PR.
The HER2 is well known as a major player in initia-
tion or progression of breast cancer, but the significance
of HER4 in breast cancer has not been studied exten-
sively. Triple-negative status of ER, PR, and HER2 was
not associated with cystatin M loss, but another triple-
negative status of ER, PR, and HER4 was significantly
associated with cystatin M loss in IBC, suggesting a dif-
ferent role of HER4 independently of HER2. Although
the interaction of HER4 with PR is not known in breast
cancer, a positive association between HER4 and ER has
been reported by many groups. HER4 overexpression in
ER-positive breast cancer cells results in enhanced cell
growth and estrogen response element (ERE)-mediated
transcriptional activity, and ectopically expressed as well
as endogenous HER4 interacts with ligand-bound ER in
response to estrogen and potentiates ER transactivation
[13,14]. Suo et al. [11] found that MCF-7 and T47-D
breast cancer cells responsive to hormonal therapy were
ER- and HER4-positive and that MDA-MD-231 and SK-
BR-3 cells nonresponsive to hormonal therapy were ER-
and HER4-negative. In addition, clinical observations
have reported that the co-expression of ER and HER4 in
breast cancer is associated with a prognostically
Figure 3 Qualitative analysis of CST6 methylation by MSP. (A)
Locations of oligonucleotide primers for methylation-specific PCR
(MSP) and pyrosequencing are shown relative to the transcriptional
start site within the human CST6 gene. “Pyro-” represents
pyrosequencing. (B) The sensitivity and specificity of the MSP
primers were verified by amplifying 100% methylated DNA and
100% unmethylated DNA with sodium bisulfite treatment. (C) MSP
for the CST6 gene was performed using methylation-specific (M)
and unmethylation-specific (U) primer sets, respectively, in formalin-
fixed paraffin-embedded tissues from IBC and DCIS. The numbers
shown are sample identification numbers. “Pos” and “Neg”
represents positive and negative controls for methylated (M) and
unmethylated (U) allele, respectively. (D) No relationship was found
between CST6 methylation by MSP and the cystatin M loss in DCIS
(P = 0.38) and IBC (P = 0.50).
Figure 4 Quantitative analysis of CST6 methylation by
pyrosequencing. (A) Representative examples of pyrosequencing
are shown in tumor and matched normal tissues. Percent indicates
the quantity of methylation at each CpG locus across all 13 CpG
dinucleotides. (B) The quantities of methylated CpGs in IBC show a
significant association with the cystatin M loss (P = 0.008) and ER
loss (P = 0.0002), but not with the PR (P = 0.64) or HER4 loss (P =
0.87). The negative and positive indicate the presence and absence
of expression of each protein, respectively. Error bars indicate a
standard deviation.
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Page 7 of 9favorable outcome [10,12,13]. The present study also
found that ER was associated with HER4 in IBCs (P =
0.01). These observations suggest that HER4 and ER
may co-operate functionally in breast cancer.
What is then the role of HER4 in the interaction with
ER in breast cancer? It has been reported that HER4 is
an estrogen-target gene, which is inducible upon E2 sti-
mulation by recruiting ER to the HER4 promoter. Once
HER4 is activated by its own ligands, such as heregulin,
HER4 is processed by TNFa-converting enzyme (TACE)
followed by g-secretase, which results in the release of
the ectodomain fragment and soluble intracellular
domain (4ICD) [20-22]. HER4 ICD has two isoforms by
alternative pre-mRNA splicing and various motifs for
association with signaling molecules, such as PI3K and
Yes-associated protein (YAP) [23,24]. HER4/4ICD pos-
sesses constitutively active kinase activity and is a cha-
perone for nuclear entry of signal transducer and
activator of transcription 5A (STAT5A). Accordingly,
HER4/4ICD forms a complex with ER and is translo-
cated into the nucleus upon estrogen stimulus, and the
nuclear ER/4ICD complex co-activates ER transcription
by being selectively recruited to estrogen responsive
gene promoters such as progesterone receptor (PgR)
[14,21]. These preclinical studies indicate that HER4
contributes to ER translocation to target genes and
functions as an ER transcriptional co-regulator, selec-
tively binding with ER to gene promoters harboring
ERE. However, it is unclear if HER4 functions as a co-
regulator of ER in the absence of ERE.
To the best of our knowledge, cystatin M has not pre-
viously been suggested as a downstream target of ER in
breast cancer. We searched for putative ER target
sequences within the promoter of the CST6 by using
the motif search program [25]. While the CST6 promo-
ter does not contain any ERE or half-ERE sites for ER
binding, it does contain binding sites for other transcrip-
tion factors such as SP-1 or AP-1. ER is also known to
interact with other transcription factors such as AP-1
and SP-1 [26,27]. These observations suggest that the
effect of ER on cystatin M expression may not be
mediated directly through ER-binding to the promoter
of the CST6 gene. Further work will be necessary to
understand possible mechanisms underlying the cystatin
M loss by ER in breast cancer.
Conclusions
The biological meaning of the cutoff criteria for positive
expression that was adopted in this study was not clear,
and poorly justified cutoffs may lead to wrong conclu-
sions and contribute to non-reproducibility of results.
The cutoff value used to define positive expression
of a protein in immunohistochemistry is of critical
importance, and a more optimal threshold should be
developed for non-biased conclusions. For the quantita-
tive analysis of methylation status in IBC, this study was
severely limited by the small number of fresh-frozen tis-
sues (51 samples) which may have led to an incorrect
conclusion between ER expression and CST6 methyla-
tion. Furthermore, patient prognosis according to cysta-
tin M loss was not analyzed due to a short period of
follow-up. Accordingly, additional work in a large num-
ber of samples will also be required to precisely deter-
mine the role of cystatin M as a prognostic marker and
to understand the association of epigenetic modification
with cystatin M loss. Taken together, the present study
suggests that cystatin M loss in IBC may be associated
with triple negative status of ER, PR, and HER4.
Abbreviations
DCIS: ductal carcinoma in situ; ER: estrogen receptor; ERE: estrogen response
element; IBC: invasive breast cancer; ICD: intracellular domain; IS:
immunoreactive score; MSP: methylation-specific; PBS: phosphate-buffered
saline; PCR: polymerase chain reaction; PR: progesterone receptor; SDF-1:
stromal cell-derived factor 1; STAT5A: signal transducer and activator of
transcription 5A; TACE: TNFa-converting enzyme; TMA: tissue microarray;
TNBCs. Triple-negative breast cancers; TNM: tumor-node-metastasis; YAP: Yes-
associated protein.
Acknowledgements
The authors wish to thank So-Hee Jung for data collection and Suh-Kyu Park
for sample collection. This work was supported by grants from the SRC/ERC
program of NRF/KOSEF (R11-2005-017-06002-0), the National R&D Program
for Cancer Control, Ministry of Health & Welfare (#0820160), and the
Research Program of dual regulation mechanisms of aging and cancer from
KOSEF (20090093587).
Author details
1Department of Molecular Cell Biology, Sungkyunkwan University School of
Medicine, 300 Cheoncheon-dong, Jangan-gu, Suwon, Gyeonggi-do 440-746,
Korea.
2Department of Pathology, Samsung Medical Center, Sungkyunkwan
University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710,
Korea.
3Functional Genomics Branch, National Cancer Center, 111
Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Korea.
4Department of Surgery, Samsung Medical Center, Sungkyunkwan University
School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea.
Authors’ contributions
EK, SEP, YK, and JAH carried out the experiments and some data analysis.
YSL, SJN, SB, JP and DHK participated in study design and data
interpretation. EK, SEP, and YK conducted sample collection and
immunohistochemistry under the supervision of EYC. EK, SEP and DHK
drafted the manuscript. All authors had final approval of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 31 August 2010 Revised: 20 October 2010
Accepted: 23 November 2010 Published: 23 November 2010
References
1. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G,
Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N,
Geller BM: Detection of ductal carcinoma in situ in women undergoing
screening mammography. J Natl Cancer Inst 2002, 94:1546-1554.
2. Leonard GD, Swain SM: Ductal carcinoma in situ, complexities and
challenges. J Natl Cancer Inst 2004, 96:906-920.
Ko et al. Breast Cancer Research 2010, 12:R100
http://breast-cancer-research.com/content/12/6/R100
Page 8 of 93. Sotiropoulou G, Anisowicz A, Sager R: Identification, cloning, and
characterization of cystatin M, a novel cysteine proteinase inhibitor,
down-regulated in breast cancer. J Biol Chem 1997, 272:903-910.
4. Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, Sloane BF, Miller FR,
Meschonat C, Li BD, Abreo F, Keppler D: Cystatin m: a novel candidate
tumor suppressor gene for breast cancer. Cancer Res 2004, 64:6957-6964.
5. Rivenbark AG, Jones WD, Risher JD, Coleman WB: DNA methylation-
dependent epigenetic regulation of gene expression in MCF-7 breast
cancer cells. Epigenetics 2006, 1:32-44.
6. Schagdarsurengin U, Pfeifer GP, Dammann R: Frequent epigenetic
inactivation of cystatin M in breast carcinoma. Oncogene 2007,
26:3089-3094.
7. Song J, Jie C, Polk P, Shridhar R, Clair T, Zhang J, Yin L, Keppler D: The
candidate tumor suppressor CST6 alters the gene expression profile of
human breast carcinoma cells: down-regulation of the potent mitogenic,
motogenic, and angiogenic factor autotaxinv. Biochem Biophys Res
Commun 2006, 340:175-182.
8. Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, Sotiropoulou G, Sloane BF,
Keppler D: Cystatin M suppresses the malignant phenotype of human
MDA-MB-435 S cells. Oncogene 2004, 23:2206-2215.
9. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH,
Davuluri RV, Plass C, Nephew KP, Huang TH: Loss of estrogen receptor
signaling triggers epigenetic silencing of downstream targets in breast
cancer. Cancer Res 2004, 64:8184-8192.
10. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW,
Robertson JF, Nicholson RI: c-erbB3 and c-erbB4 expression is a feature of
the endocrine responsive phenotype in clinical breast cancer. Oncogene
1998, 17:1949-1957.
11. Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM: Estrogen receptor-
alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 2001,
439:62-69.
12. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ: Absence
of HER4 expression predicts recurrence of ductal carcinoma in situ of
the breast. Clin Cancer Res 2005, 11:2163-2168.
13. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P,
Joensuu H, Isola J, Elenius K: Cleavable ErbB4 isoform in estrogen
receptor-regulated growth of breast cancer cells. Cancer Res 2005,
65:1384-1393.
14. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L,
Vadlamudi RK, Jones FE: Coregulation of estrogen receptor by ERBB4/
HER4 establishes a growth-promoting autocrine signal in breast tumor
cells. Cancer Research 2006, 66:7991-7998.
15. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F,
Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G: Tissue
microarrays for rapid linking of molecular changes to clinical endpoints.
Am J Pathol 2001, 159:2249-2256.
16. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-
specific PCR: a novel PCR assay for methylation status of CpG islands.
Proc Natl Acad Sci USA 1996, 93:9821-9826.
17. Hewitt SC, Korach KS: Progesterone action and responses in the alpha
ERKO mouse. Steroids 2000, 65:551-557.
18. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB:
Differential gene regulation by the two progesterone receptor isoforms
in human breast cancer cells. J Biol Chem 2002, 277:5209-5218.
19. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB: New human breast
cancer cells to study progesterone receptor isoform ratio effects and
ligand-independent gene regulation. J Biol Chem 2002, 277:27793-27800.
20. Rio C, Buxbaum JD, Peschon JJ, Corfas G: Tumor necrosis factor-a-
convertingenzym e is required for cleavage of erbB4/HER4. J Biol Chem
2000, 275:10379-10387.
21. Ni C-Y, Murphy MP, Golde TE, Carpenter G: γ-secretase cleavage and
nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001,
294:2179-2181.
22. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, Kim TW: Presenilin-
dependent γ-secretase-like intramembrane cleavage of ErbB4. J Biol
Chem 2002, 277:6318-6323.
23. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M:
Characterization of a naturally occurring ErbB4 isoform that does not
bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999,
18:2607-2615.
24. Long W, Wagner KU, Lloyd KC, Binart N, Shillingford JM, Hennighausen L,
Jones FE: Impaired differentiation and lactational failure of Erbb4-
deficient mammary glands identify ERBB4 as an obligate mediator of
STAT5. Development 2003, 130:5257-5268.
25. GenomeNet Database Resources. [http://www.genome.jp].
26. Cheung E, Acevedo ML, Cole PA, Kraus WL: Altered pharmacology and
distinct coactivator usage for estrogen receptor-dependent transcription
through activating protein-1. Proc Natl Acad Sci USA 2005, 102:559-564.
27. Schultz JR, Petz LN, Nardulli AM: Cell- and ligand-specific regulation of
promoters containing activator protein-1 and Sp1 sites by estrogen
receptors alpha and beta. J Biol Chem 2005, 280:347-354.
doi:10.1186/bcr2783
Cite this article as: Ko et al.: Cystatin M loss is associated with the
losses of estrogen receptor, progesterone receptor, and HER4 in
invasive breast cancer. Breast Cancer Research 2010 12:R100.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ko et al. Breast Cancer Research 2010, 12:R100
http://breast-cancer-research.com/content/12/6/R100
Page 9 of 9